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Abstract
Accumulating evidence suggests that breast cancer metastatic progression is modified by germline polymorphism,
although specific modifier genes have remained largely undefined. In the current study, we employ the MMTV-PyMT
transgenic mouse model and the AKXD panel of recombinant inbred mice to identify AT–rich interactive domain 4B (Arid4b;
NM_194262) as a breast cancer progression modifier gene. Ectopic expression of Arid4b promoted primary tumor growth in
vivo as well as increased migration and invasion in vitro, and the phenotype was associated with polymorphisms identified
between the AKR/J and DBA/2J alleles as predicted by our genetic analyses. Stable shRNA–mediated knockdown of Arid4b
caused a significant reduction in pulmonary metastases, validating a role for Arid4b as a metastasis modifier gene. ARID4B
physically interacts with the breast cancer metastasis suppressor BRMS1, and we detected differential binding of the Arid4b
alleles to histone deacetylase complex members mSIN3A and mSDS3, suggesting that the mechanism of Arid4b action likely
involves interactions with chromatin modifying complexes. Downregulation of the conserved Tpx2 gene network, which is
comprised of many factors regulating cell cycle and mitotic spindle biology, was observed concomitant with loss of
metastatic efficiency in Arid4b knockdown cells. Consistent with our genetic analysis and in vivo experiments in our mouse
model system, ARID4B expression was also an independent predictor of distant metastasis-free survival in breast cancer
patients with ER+ tumors. These studies support a causative role of ARID4B in metastatic progression of breast cancer.
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Introduction
Breastcancerremains the most commonlydiagnosedmalignancy
among women in the UnitedStates [1]. Because the vast majority of
breast cancer related mortality is attributable to disseminated
metastatic disease, a clear need exists to identify factors that
modulate breast cancer metastatic progression. In addition to
acquired somatic mutations, there is accumulatingevidence that the
genetic background on which a tumor arises can influence disease
progression [2]. Identifying and characterizing metastasis suscepti-
bility genes would provide additional insights into the mechanisms
associated with tumordisseminationand growth,leadingnotonlyto
better understanding of this complex process but also ultimately to
new targets and strategies for clinical intervention.
Due to the complex interactions between inherited factors and
somatic mutations in metastatic progression, as well as the genetic
complexity of human populations, identification of inherited
susceptibility genes directly in human populations is difficult. To
circumvent this our laboratory has chosen to apply a systems
genetics approach on a mouse model of metastatic luminal breast
cancer, the FVB/N-TgN(MMTV-PyMT)
634Mul (MMTV-PyMT)
transgenic model. The MMTV-PyMT transgenic mouse model,
which expresses the polyoma virus middle T antigen under the
control of the mouse mammary tumor virus promoter, rapidly
develops tumors in approximately 100% of female mammary
glands and .85% of these animals develop pulmonary metastases
by 14 weeks of age. When the MMTV-PyMT model is bred onto
a variety of different mouse strains, the F1 progeny display broad
and strain-dependent heterogeneity in primary tumor latency,
primary tumor growth rate and lung metastatic density [2].
Two strains, the highly metastatic AKR/J and poorly metastatic
DBA/2J, were found to have a 20-fold difference in their
metastatic capacity but no significant difference in any other
measured tumor phenotype. These strains were also the progenitor
strains for the AKXD recombinant inbred panel of mice, which
consists of more than 20 substrains that are composites of the
original parental strains AKR/J and DBA/2J. The MMTV-
PyMT model was therefore bred to 18 different AKXD strains,
the F1 mice were phenotyped with respect to primary tumor
latency and burden and lung metastatic density, and the
phenotypes were compared to haplotype maps of the AKXD
strains to determine quantitative trait loci (QTLs) associated with
mammary tumor progression [3]. Subsequently, RNA was also
harvested from F1 tumors and gene expression analysis was
performed to define individual genes whose expression correlated
with progression [4].
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as a novel candidate metastasis susceptibility gene. Although the
precise molecular functions of ARID4B are unknown, it has been
shown to associate with the SIN3A histone deacetylase (HDAC)
complex [5]. As predicted by the genetic linkage and gene
expression data, higher expression of Arid4b is associated with
more rapid tumor growth in animal models, as well as increased
tumor cell motility and invasion. These effects are associated with
differential binding of the AKR and DBA alleles of ARID4B to
HDAC complex members mSIN3A and mSDS3. ARID4B was
also found to bind the mSIN3A-associated breast cancer
metastasis suppressor protein BRMS1. Stable shRNA-mediated
knockdown of Arid4b significantly inhibited the pulmonary
metastatic efficiency of orthotopic mammary tumors without
inhibiting primary tumor growth. Consistent with impaired
metastasis in the Arid4b knockdown lines was decreased expression
of a recently described metastasis-predictive gene network [6].
High expression of ARID4B was associated with an approximately
2-fold increased risk of metastatic progression in human breast
cancer patients who were lymph node negative at diagnosis. Taken
together these results demonstrate a causal role for Arid4b in tumor
growth and metastatic progression and suggest that mechanisms of
action involve modification of epigenetic state via the mSIN3A
complex and regulation of the conserved Tpx2 gene network.
Results
Identification of Arid4b as a potential tumor progression
gene
Previously a cross between the highly metastatic PyMT model
and the AKXD recombinant inbred (RI) panel was performed to
map QTLs associated with inherited predisposition to developing
pulmonary metastasis [3]. In addition to metastasis susceptibility
loci on chromosomes 6 and 19, linkage analysis revealed a
potential peak on proximal chromosome 13 (Figure S1). In a
subsequent study, gene expression analysis was also carried out on
these samples to examine the effect of varying metastatic
genotypes on tumor transcriptional patterns [7]. To discover
potential candidate genes that may affect metastatic predisposi-
tion, correlation analysis was performed using GeneNetwork [8] to
identify genes whose differential expression was highly associated
with metastasis. Upon integrating the data from these two studies
we found that of the top ten genes most significantly associated
with metastasis in our expression correlation analysis, two also
mapped to potential QTLs: Ttc9c and Arid4b. The potential role of
Ttc9c was investigated and no significant differences were detected
with respect to orthotopic tumor growth or metastasis of 6DT1
mouse mammary carcinoma cells stably expressing Ttc9c com-
pared to vector control cells (data not shown). Similarly, we
detected no significant effects on tumor growth or metastasis when
Ttc9c BAC transgenic mice were bred to the MMTV-PyMT
model (data not shown). The most likely explanation for why Ttc9c
did not pass our validation experiments is that its initial
identification in our screens was a false positive owing to its close
physical proximity on chromosome 19 to the metastasis modifier
gene Sipa1 [9]. Our current studies have therefore focused on
Arid4b, which maps within the chromosome 13 locus and whose
mRNA expression was positively associated with metastatic disease
and tumor growth (Figure 1), suggesting a possible causative role
as a progression modifier.
Figure 1. Arid4b expression is correlated with tumor growth
and metastasis. Gene expression microarray data from 18 of the
AKXD recombinant inbred strains shows expression of Arid4b is
positively correlated with tumor burden (A) and metastatic density
(B). The formula used to calculate metastatic density was ln[(metas-
tases/um
2)610
8].
doi:10.1371/journal.pgen.1002735.g001
Author Summary
A person’s individual genetic background influences not
only the likelihood of developing breast cancer, but also
the likelihood of that cancer becoming metastatic. The
identification of metastasis susceptibility genes using
human samples is rendered impractical by the high degree
of genetic diversity among people. Our laboratory’s
strategy is to cross genetically defined inbred mouse
strains to recapitulate a degree of genetic diversity that is
more readily studied. By breeding these panels of inbred
mouse crosses to a mouse model of breast cancer, we can
identify regions of the genome that correlate with
observed phenotypic variation including metastatic den-
sity and then identify individual candidate genes. This
manuscript describes the identification of Arid4b as a
candidate gene of interest and the experiments we
performed to validate its role in metastasis. High expres-
sion of Arid4b enhances cell migration and invasion and,
conversely, knockdown of Arid4b inhibits metastasis of
breast tumor cells to the lungs. The mouse gene and
human ARID4B are highly conserved, and among women
with ER+ tumors ARID4B expression level is predictive of
which patients will progress to develop metastatic disease.
Arid4b Promotes Progression of Breast Cancer
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between AKR and DBA
To validate the potential differences in Arid4b expression
between strains, microarray data from AKR and DBA normal
tissues were examined [4]. Consistent with the AKXD RI results,
Arid4b expression was 2.3-fold higher in thymus (p=9.32610
25,
FDR=0.0004) and 2.5-fold higher in bone marrow
(p=1.28610
25, FDR=0.0005) of DBA mice compared to
AKR, suggesting that constitutional polymorphisms can influence
Arid4b expression levels in normal tissues. Sequence analysis was
also performed to both validate SNPs in the public database as
well as identify potential new variants between the AKR and DBA
alleles of Arid4b. Complete exon sequencing revealed that the DBA
allele matched the consensus C57BL/6 sequence. Analysis of the
AKR allele revealed numerous silent SNPs as well as polymor-
phisms encoding eleven amino acid substitutions, as shown in
Figure 2. Interestingly, eight of these eleven polymorphisms are
located in exon 22 and their encoded substitutions are densely
clustered towards the C-terminal end between amino acids 1171
and 1198. These results are consistent with the possibility that
inherited variation of Arid4b may contribute to tumor progression.
Arid4b expression promotes primary tumor growth
Analysis of the data revealed that increased Arid4b expression
and increased metastatic susceptibility were associated with the
DBA rather than the AKR genotype at the chromosome 13 QTL.
This result suggests that the DBA allele at this locus promoted
metastatic progression relative to the AKR allele, and a series of in
vitro and in vivo assays were performed to test this hypothesis. V5-
tagged AKR and DBA alleles of Arid4b were ectopically expressed
in the mouse mammary carcinoma cell line Met-1, which was
originally derived from tumors arising in the MMTV-PyMT
transgenic model [10]. Because the Met-1 line was derived from
an FVB strain background, we also sequenced the FVB allele of
Arid4b and found it to be identical to the DBA and C57BL/6
alleles. Cell lines were then identified that expressed the epitope
tagged constructs at levels that were only two to three-fold higher
than endogenous levels as measured by QRT-PCR (Figure S2A),
consistent with the approximately two-fold range of Arid4b mRNA
between high and low metastatic AKXD strains. Furthermore, the
ectopically expressed AKR and DBA alleles were detected at
approximately equal levels in our stable lines as assessed by
western blots (Figure S2B).
Orthotopic implantation assays were then performed to
examine the role of Arid4b expression in vivo (Figure 3A). By four
weeks post-implantation, cells expressing the DBA allele formed
tumors with a 2.6-fold larger mass compared to control cells
(741 mg versus 284 mg; p=6.08610‘27). The AKR allele
expressing cells formed tumors with a median mass of 480 mg,
which was significantly larger than control tumors (p=0.010) but
significantly smaller than the DBA cohort (p=7.73610‘23),
consistent with our previous genetic analysis and our in vitro
studies.
DBA Arid4b promotes increased in vitro tumor invasion
and migration compared to AKR
In vitro assays were performed to address the potential affect of
the Arid4b polymorphisms on tumor cell behavior. In vitro growth
assays demonstrated no significant difference in proliferation
between cells expressing the DBA or AKR alleles or control cells
(data not shown). In contrast, ectopic expression of either allele
significantly increased the abilities of Met-1 cells to migrate
through a porous membrane and to invade through Matrigel,
compared to control cells expressing lacZ (Figure 3B). Notably,
Met-1 cells stably expressing the DBA allele were significantly
more migratory and invasive than those expressing the AKR
allele. Since both cell lines express the epitope-tagged construct at
approximately the same level, these results suggest a potential
functional consequence for the amino acid substitutions present
between the two variants in addition to the effects associated with
differential expression.
Knockdown of Arid4b inhibits pulmonary metastasis
Because Met-1 cells are poorly metastatic in our laboratory, and
because we were unable to stably overexpress Arid4b in several
more aggressive mouse breast cancer cell lines, we adopted a
knockdown strategy to examine the role of Arid4b in lung
metastasis in vivo. To this end, the highly metastatic 6DT1 cell
line [11] was transduced with five lentiviral shRNAs targeting
Arid4b, or a scrambled control, and knockdown of ARID4B
protein was evaluated using western blots (Figure 4A) and
densitometry (Figure 4B) to select stable shRNA lines for in vivo
studies. No significant knockdown was observed using the
scrambled control shRNA. Cells stably transduced with Arid4b
shRNAs designated H3 and H4 expressed 81% and 85% less
ARID4B protein, respectively, compared to controls, and were
therefore selected for further in vivo study.
Following orthotopic implantation of 10‘5 cells into the
mammary fat pad we observed only slight differences in median
primary tumor mass between the scrambled control, H3, and H4
cohorts, and these data did not achieve statistical significance
(p=.070, Kruskal-Wallis; Figure 4C). In contrast, we observed a
2-fold decrease in the median number of macroscopic lung
metastases in the H3 cohort (10 vs. 22; p=.013) and a 7-fold
decrease in the H4 cohort (3 vs. 22; p=9.72610‘25) compared to
controls (Figure 4D). Differences in lung metastasis between the
two Arid4b knockdown cohorts were not statistically significant
following post hoc testing (p=.066, Conover-Inman). These data
Figure 2. Arid4b germline amino acid sequence variants. Substitutions in the AKR allele are shown relative to a consensus sequence that is
identical between DBA, FVB, and C57Bl/6. The+symbol indicates conserved substitutions.
doi:10.1371/journal.pgen.1002735.g002
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of pulmonary metastatic efficiency in this model system.
Arid4b germline polymorphism modifies binding to
mSIN3A
Previous studies demonstrated that ARID4B is a member of the
mSIN3A HDAC complex and that binding to mSIN3A involves
the C-terminal domain of ARID4B [5], where the majority of the
amino acid substitutions were found between the AKR and DBA
variants (Figure 2). Co-IP analysis was therefore performed to
examine a potential effect of the observed amino acid substitutions
on ARID4B-mSIN3A binding. For these experiments V5-tagged
ARID4B was transiently transfected into HEK293 cells and
immunoprecipitated using an anti-V5 antibody. Binding to
endogenous mSIN3A and another component of the mSIN3A
complex, mSDS3 [12], was evaluated by western blots (Figure 5).
Input controls for ARID4B, mSIN3A, and mSDS3 were
approximately equal as were the amounts of the two Arid4b
variants immunoprecipitated; however, a marked decrease in
binding to mSIN3A was observed along with diminished mSDS3
association for the DBA variant (Figure 5A). Densitometry analysis
revealed that binding of the DBA variant was reduced by 51% and
37% for mSIN3A and mSDS3, respectively, compared to AKR
(Figure 5B). These results demonstrate a functional consequence of
Arid4b polymorphisms and provide insight into one potential
molecular mechanism whereby Arid4b may modulate breast cancer
progression.
ARID4B binds the breast cancer metastasis suppressor
BRMS1
Breast cancer metastasis suppressor 1 (BRMS1) belongs to the
same family of proteins as mSDS3 and is known to associate with
the mSIN3A complex as well as ARID4A [13]. Because ARID4B
is also known to bind mSIN3A, mSDS3, and ARID4A [14], we
postulated that ARID4B might physically bind BRMS1. Proteo-
mics screens to identify BRMS1 interacting proteins also support
this association: in a yeast two-hybrid screen for proteins binding
full-length BRMS1, ARID4B was the number one hit identified,
and ARID4A and mSDS3 were also detected (unpublished data).
In a separate screen, mass spectrometry was performed to identify
mSIN3A binding proteins in MCF10A human breast epithelial
cells. Peptides representing endogenous ARID4B and BRMS1
were detected, providing further evidence for this interaction and
demonstrating that it is not simply an artifact of supraphysiologic
expression in transfected cells (Douglas Hurst; personal commu-
nication). To validate this interaction we performed co-IPs using
lysates from 293 cells transiently transfected with the FLAG-
tagged AKR or DBA variants of ARID4B along with either HA-
or myc-tagged BRMS1. HA-BRMS1 was readily detected
following pull-down of ARID4B using an anti-FLAG antibody
(Figure 6A). Likewise, ARID4B was efficiently co-precipitated with
myc-BRMS1 (Figure 6B). Unlike the associations with mSIN3A
and mSDS3 however, the AKR and DBA variants of ARID4B did
not exhibit differential binding to BRMS1. One possible
explanation for this observation is that BRMS1 binds to a
different region of ARID4B than the polymorphic C-terminal
domain that mediates binding to mSIN3A.
Arid4b regulates the metastasis-associated TPX2 gene
network
Because little is known about the specific cellular processes
regulated by Arid4b that might influence the metastatic phenotype,
we performed expression microarray analysis on the 6DT1 cell
lines stably expressing Arid4b shRNAs to identify genes that are
differentially expressed as a function of Arid4b levels. Based on the
western blot densitometry shown in Figure 4A–4B cell lines
Figure 3. Ectopic expression of Arid4b increases orthotopic tumor growth, tumor cell migration, and invasion. Scatter plot bars
represent median tumor mass (A) four weeks after orthotopic implantation of 10‘5 cells stably expressing lacZ (n=20), Arid4b AKR allele (n=17) or
Arid4b DBA allele (n=20). Migrating and invading cells (B) were counted in five 4006fields per experiment and data are presented as the mean 6
standard error of three independent experiments. Statistical significance was determined using Kruskal-Wallis tests followed by Conover-Inman post
hoc tests. *, p,0.05; ***, p,0.001.
doi:10.1371/journal.pgen.1002735.g003
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Arid4b knockdown cohort, and the control cohort consisted of
untreated 6DT1 cells and lines expressing the scrambled control
shRNA or hairpin H5. We detected 2,048 unique genes whose
expression was significantly different (p,0.05, ANOVA) between
the two groups and those with the greatest fold change are
summarized in Table 1. While the most highly upregulated genes
function in pathways with diverse biological roles, it was noted that
among the most downregulated genes were multiple factors
associated with centromeres (Cenpi, Cenpq), microtubule and
spindle dynamics (Kif2c, Kif4a, Sass6), and cell cycle regulation
(Ccne, Cdc25c). Consistent with this observation were the results of
pathway analysis conducted to identify biological functions
impacted as a consequence of Arid4b knockdown (Table 2). The
most differentially regulated processes based on gene ontology
were checkpoint control and DNA repair, and processes related to
centrosome, centriole, and chromosome dynamics.
In examining the microarray data we noticed a striking overlap
between genes downregulated in the Arid4b knockdown lines and
components of the TPX2 gene network. This transcriptional
network was recently identified based on expression profiling of
three mouse data sets and two human breast cancer data sets [6].
The TPX2 network is tumor cell-autonomous and conserved
across species, its activation is predictive of reduced distant
metastasis-free survival (DMFS) in ER-positive patients, and the
nine common hub genes in the TPX2 signature (TPX2, BUB1,
UBE2C, CDC20, CCNB2, KIF2C, BUB1B, CEP55, CENPA) that
were conserved across all five data sets consist primarily of genes
involved in microtubule and mitotic spindle function. To
determine how Arid4b levels influence the activation state of the
TPX2 network, the fold changes of the 311 TPX2 network genes
were examined in the Arid4b knockdown lines. Compared to
control cell lines, 119 network genes were significantly downreg-
ulated (p,0.05) including Tpx2 itself and the other eight common
hub genes, versus only 5 network genes upregulated (Figure 7; high
resolution available as Figure S3). The downregulation of this gene
network concomitant with the inhibition of metastasis observed in
the Arid4b knockdown lines provides further support for the role of
the TPX2 network in metastatic susceptibility and suggests that a
significant portion of this network may be regulated by Arid4b.
High Arid4b expression predicts poor clinical outcome
Because Arid4b was identified as a candidate gene in part based
on differential expression between high and low metastatic strains
of mice in the AKXD panel, and because Arid4b expression levels
were associated with tumor growth and metastasis in mice as well
Figure 4. Stable shRNA–mediated knockdown of Arid4b inhibits lung metastasis. ARID4B protein levels were analyzed by western blot to
determine level of knockdown in cell lines stably expressing different Arid4b shRNAs. Experiment was performed in triplicate and a representative
blot is shown in panel A. Lysate from 293 cells transiently transfected with Arid4b was used as a positive control (+C). Untransduced 6DT1 and
scrambled control lines are designated ‘‘untr’’ and ‘‘scr’’ respectively. The lower non-specific (n.s.) band most likely represents ARID4A, based on a
nearly identical epitope sequence and consistent with the observed difference in molecular weight. Expression of the non-specific band remained
relatively unchanged across the panel of stable lines. Densitometry was performed to quantitate knockdown at the protein level in the Arid4b shRNA
lines relative to the scrambled control line (B) Data are shown as the mean 6 standard error of three independent experiments. Kruskal-Wallis
followed by Conover-Inman post hoc tests were used to determine statistical significance versus the scrambled control cell line. *, p,.05; **, p,.01;
***, p,.001. Primary tumors were weighed (C) and lung surface metastases were counted (D) at 3.5 weeks after orthotopic implantation of 10‘5 cells
from the scrambled control, H3, and H4 lines into the mammary fat pad of FVB mice (n=10 per cohort). Horizontal bars represent median values and
statistical significance was determined using Kruskal-Wallis tests followed by Conover-Inman correction for multiple comparisons.
doi:10.1371/journal.pgen.1002735.g004
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tested whether ARID4B expression alone correlated with human
patient outcomes. A search of publically available breast cancer
microarray data sets using Oncomine (Compendia Bioscience,
Ann Arbor, MI) revealed that ARID4B expression was 2.3-fold
higher in 40 ductal breast carcinoma samples compared to 7
normal breast tissue samples in the Richardson study [15],
confirming that high ARID4B expression is clinically associated
with breast cancer (Figure S4). Analysis of a pooled breast cancer
dataset using GOBO (http://co.bmc.lu.se/gobo/) [16] showed
that among the subgroup of patients with ER-positive tumors, the
cohort with high expression of ARID4B had significantly reduced
DMFS compared to the low or median ARID4B cohorts (Figure 8).
Because this association was significant among patients with ER-
positive tumors who were lymph node negative at the time of
diagnosis (Figure 8A), this finding indicated that ARID4B
expression level is predictive of patient progression to metastatic
disease. As determined by multivariate analysis (Figure 8B), the
hazard ratio compared to the high ARID4B tercile was 0.54 for
middle ARID4B (95% C.I.=0.33–0.89; p=.015) and 0.42 for the
low ARID4B tercile (95% C.I.=0.26–0.70; p=7.51610‘24),
indicating that patients with tumors expressing high levels of
ARID4B are approximately twice as likely to develop metastatic
disease. The association of ARID4B with reduced DMFS was also
highly significant among ER-positive patients not receiving
adjuvant therapy (Figure 8C–8D), indicating that ARID4B
expression level plays a significant role in the natural metastatic
progression of ER-positive breast cancer in human patients and its
relevance is not confined solely to our mouse model systems.
Discussion
Arid4b was identified as a candidate gene of interest through
linkage and expression correlation analyses, and the in vitro and in
vivo data presented here provide the first direct evidence of a causal
role of Arid4b in mammary tumor progression and metastasis. The
initial QTL analysis revealed association with Arid4b on proximal
chromosome 13, and Arid4b was among the most highly correlated
genes with the most significant p values in the subsequent eQTL
analysis in the AKXD recombinant inbred panel. It was noted that
although AKR/J is the more highly metastatic of the two parental
strains, progression was associated with the DBA/2J allele,
suggesting that the metastasis promoting influence of Arid4b is
likely masked by other suppressive factors in a pure DBA/2J
background. Although the AKXD recombinant inbred panel lacks
the power to detect these epistatic interactions, ongoing experi-
ments using the latest generation of recombinant inbred mice
including the Collaborative Cross [17,18] will enable higher
resolution QTL mapping and more robust systems genetics
analyses going forward.
Figure 5. Differential binding of the AKR and DBA variants of
ARID4B to the mSIN3A complex. Western blots (A) show equivalent
input of V5-ARID4B, mSIN3A, mSDS3, and equivalent pull-down of the
two variants using an anti-V5 antibody. Decreased binding of the DBA
variant of ARID4B to mSIN3A and mSDS3 was observed relative to the
AKR variant. Experiment was performed in triplicate and densitometry
analysis (B) revealed a 51% reduction in mSIN3A binding (p=.037) and a
37% reduction in mSDS3 binding (p=.026) for the DBA variant relative
to AKR. Statistical significance was determined using paired t-tests. *,
p,.05.
doi:10.1371/journal.pgen.1002735.g005
Figure 6. ARID4B binds BRMS1. HA-BRMS1 was coprecipitated with FLAG-ARID4B (A) and FLAG-ARID4B was coprecipitated with myc-BRMS1 (B).
No difference in binding to BRMS1 was observed between the AKR and DBA alleles of ARID4B.
doi:10.1371/journal.pgen.1002735.g006
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89% identity and 95% similarity to the 1312 amino acid human
protein. Alternate nomenclature includes breast cancer-associated
antigen 1 (BRCAA1), retinoblastoma-binding protein-1-like pro-
tein-1 (RBP1L1), and mSIN3A-associated protein of 180 kDa
(SAP180). Indeed, there are multiple lines of evidence implicating
Arid4b in breast cancer. A ten amino acid peptide was found to
represent an antigen epitope expressed in 65% of breast cancer
specimens and was significantly upregulated in the sera of breast
cancer patients compared to healthy donors [19]. ARID4B was
also found to associate with the mSIN3A HDAC complex [5],
which is in turn known to be bound by the breast cancer
associated tumor suppressor ING1 [20,21], the well-characterized
breast cancer metastasis suppressor BRMS1 [13], and the ARID
family homolog ARID4A/RBP1 [22], which has also been
identified as a breast cancer associated antigen [23].
Ectopic expression of Arid4b at a physiologically relevant two- to
three-fold increased level resulted in a 3-fold increase in orthotopic
tumor mass relative to controls for Met-1 cells expressing the DBA
allele, while the AKR allele induced 1.9-fold larger tumors versus
control cells. To our knowledge, this is the first direct evidence that
Arid4b upregulation promotes tumor growth. Although Met-1
orthotopic tumors do not readily metastasize in our experience,
transwell assays in vitro demonstrated that upregulation of either
allele of Arid4b increased tumor cell migration and invasion,
consistent with a role of Arid4b in metastatic progression, and cells
expressing the DBA allele were significantly more migratory and
invasive than cells expressing the AKR allele. While stable
upregulation of Arid4b did not induce Met-1 cells to metastasize
with any greater frequency, stable knockdown of Arid4b in the
highly metastatic 6DT1 cell line did cause a dramatic reduction in
pulmonary metastases, raising the possibility that ARID4B may
represent a novel therapeutic target. Taken together, the results of
the orthotopic implantation and transwell assays are broadly
consistent with our genetic linkage and expression correlation
analyses that showed an association of the DBA haplotype on
chromosome 13 with metastatic progression in the MMTV-
PyMT6AKXD mice, and validate a functional role of Arid4b
polymorphism in modulating the breast cancer phenotype.
While the molecular mechanisms of Arid4b are incompletely
understood, an examination of its sequence and conserved
domains provides further insight into its potential functions.
Arid4b contains a nuclear localization signal (NLS) towards the C-
terminus as well as conserved Tudor, RBB1NT, ARID/BRIGHT,
and Chromo domains in the N-terminal half of the protein. The
ARID domain mediates binding to DNA, although the affinity for
AT-rich sequences varies among members of the Arid superfamily
[24,25]. The RBB1NT domain is present in many Rb binding
proteins including ARID4A, although it is noteworthy that unlike
ARID4A, ARID4B does not contain the LCXCE motif necessary
for RB binding [26], and no interaction was observed when we
attempted to co-IP ARID4B with RB (data not shown); therefore,
the function of the RBB1NT domain of ARID4B remains
uncertain. Tudor domains are present in many RNA binding
proteins [27] and also bind methylated lysine residues on histone
tails [28]. Chromo domain-containing proteins have also been
shown to bind methylated lysines and mediate the recruitment of
chromatin modifying complexes [29]. Because mSIN3A itself lacks
intrinsic DNA binding capability, targeting of mSIN3A-associated
HDAC activity depends on interactions with other transcription
factors including Mad1 and KLF repressors among others [30].
The presence of putative DNA and histone binding domains in the
N-terminal half of ARID4B suggest that its influence on mammary
tumor progression involves directing the HDAC activity of
mSIN3A complexes to chromatin. This is supported by our
observations that the high and low metastatic alleles of ARID4B
have a dense cluster of amino acid polymorphisms in the C-
terminal domain and bind with different affinities to mSIN3A and
mSDS3, though the biochemical significance of this observation
remains to be determined. Diminished expression levels or binding
affinity of ARID4B may allow mSIN3A to be bound by other
proteins with different DNA sequence specificity, perhaps not
Table 2. Cellular processes regulated by Arid4b knockdown.
Biological function z-score p-value # of genes
Checkpoint control 22.833 1.29E216 33
DNA repair 22.660 2.93E212 58
Cycling of centrosome 22.914 3.95E210 21
Formation of centriole 22.565 8.44E209 12
Replication of centriole 22.268 5.77E208 11
S phase checkpoint control 22.119 1.58E207 10
Repair of cells 22.168 8.06E207 18
Orientation of chromosomes 22.386 2.06E206 11
Transcription 22.670 2.50E205 259
Damage of chromosomes 2.157 4.02E204 9
Cell death 2.172 6.06E204 28
DNA damage 2.190 2.05E203 24
Biological processes are listed in order of statistical significance after applying a
cutoff based on z-scores with an absolute value greater than 2. Negative z-
scores indicate downregulation; positive z-scores indicate upregulation.
doi:10.1371/journal.pgen.1002735.t002
Table 1. Genes most highly up- or down-regulated following
Arid4b knockdown.
Gene Fold Change p-value
Sprr1b 2.931 2.31E202
Btg2 2.761 7.99E203
Ctxn1 2.341 1.93E202
Pmm1 2.274 1.44E203
Zmat3 2.097 8.27E203
Gm5617 2.080 1.88E202
Tp53inp1 2.065 2.32E202
Sesn2 1.998 5.59E204
Gramd1a 1.965 1.30E202
Ak1 1.946 6.52E203
Cenpi 23.457 9.76E203
Kif2c 23.403 2.56E204
Ccne2 23.198 4.00E203
Gpr116 22.975 2.21E204
P4ha3 22.937 4.32E202
Kif4a 22.882 1.41E202
Ncapg2 22.777 2.49E202
Cdc25c 22.709 8.10E203
Cenpq 22.702 1.04E202
Sass6 22.701 8.76E204
doi:10.1371/journal.pgen.1002735.t001
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histone mark but rather altering the expression of different subsets
of genes.
It is noteworthy that the pro-metastatic ARID4B and the
metastasis suppressive BRMS1 bind each other and also to the
mSIN3A complex in vitro. This observation reinforces the
significance of the mSIN3A complex in metastatic progression,
and it is tempting to speculate that an HDAC complex may be
caught in a molecular tug-of-war between these two metastasis
modifier genes. However, the mSIN3A complex is modular in
nature and interacts with a great variety of transcriptional
regulators [30,31]. Many different complexes exist, and their
precise composition and function within the context of breast
cancer are not well understood. Further studies will be necessary to
define a role, if any, for the ARID4B-BRMS1 interaction in
human disease.
While ARID4B expression was not a significant predictor of
DMFS across all patients in a meta-analysis of an 1,881 sample
data set, statistical significance emerged when patients were
stratified based on ER status. The observation that ARID4B is
Figure 7. Expression of Tpx2 network genes in Arid4b knockdown cell lines. The nine labeled hub genes were conserved across mouse and
human breast cancer data sets. Red indicates statistically significant (p,.05) downregulation; green indicates upregulation.
doi:10.1371/journal.pgen.1002735.g007
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consistent with the identification of Arid4b as a candidate gene in
the context of the MMTV-PyMT mouse model system, in which
tumors arise from a predominantly ER+ luminal epithelial cell
population [32]. Loss of ER and PR is detected during progression
to late carcinomas, however in a systematic analysis of gene
expression profiles these late PyMT tumors clustered most closely
with human luminal tumors [33], which are ER+. Also consistent
with ARID4B promoting metastatic progression of ER+ tumors is
our observation that Arid4b knockdown caused a significant
downregulation of the core components of the Tpx2 gene network.
The TPX2 signature was tumor cell autonomous and predictive of
DMFS only in those patients who were ER+ at diagnosis, and was
distinct from a CD53 network that was associated with ER-
negative stromal components [6]. Polymorphisms in several other
tumor cell autonomous metastasis susceptibility genes identified in
our laboratory including Sipa1, Rrp1b, and Brd4 are prognostic
only in ER+ patients [9,34–37], and stable expression of Brd4 can
also differentially regulate the Tpx2 network [6]. The association of
multiple metastasis susceptibility genes with a transcriptional
network comprising many cell cycle and mitotic spindle check-
point regulatory genes highlights the possibility that these cellular
functions are critical determinants of metastatic efficiency. Further
experiments are underway in our laboratory to determine whether
upregulation of the TPX2 network is causative in promoting
metastasis.
Materials and Methods
Identification of Arid4b germline polymorphisms
Using genomic DNA from AKR/J and DBA/2J mice as
templates, PCR was performed to amplify the protein coding
Figure 8. High expression of ARID4B is associated with poor clinical outcome. In patients with ER-positive tumors who were node negative
at diagnosis (A) distant metastasis-free survival (DMFS) was significantly lower (p=.009) in patients with high expression (blue) compared to middle
(red) or low (gray) expression of ARID4B, and multivariate analysis of 440 cases (B) was performed to determine metastatic progression hazard ratios
of 0.54 and 0.42 for median and low ARID4B terciles, respectively, compared to the high ARID4B tercile. The association of high ARID4B with poor
DMFS was also highly significant (p=3.05610‘24) among ER-positive patients in the absence of adjuvant therapy (C) with similar hazard ratios (D) of
0.53 and 0.49 for middle and low ARID4B groups compared to high ARID4B.
doi:10.1371/journal.pgen.1002735.g008
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subjected to agarose gel electrophoresis, bands isolated using the
QIAquick Gel Extraction kit (Qiagen) according to manufacturer’s
recommendations, and used as templates for sequencing. All
sequencing runs were performed by the DNA Sequencing and
Gene Expression Core, NCI, Bethesda, MD. Genomic sequences
for the AKR and DBA alleles were aligned using pairwise BLAST
[38] and non-synonymous polymorphisms verified by manual
comparison of chromatograms using Chromas software (Techne-
lysium).
Expression vectors
V5-tagged AKR and DBA alleles of Arid4b were generated using
long range PCR with forward primer 59-AACAAAGGTG-
CAGGTGAAGC-39 and reverse primer 59-CCTGCACT-
CAACTGACATTCCATTC-39 to amplify Arid4b, and PCR
products were cloned into pcDNA3.1/V5-His-TOPO (Invitro-
gen). FLAG-tagged Arid4b vectors were constructed by the Protein
Expression Laboratory, SAIC-Frederick, Inc. using Gateway
technology (Invitrogen). Briefly, the AKR or DBA allele of Arid4b
was PCR amplified and cloned into entry vector pDonr-253, then
subcloned by Gateway LR recombination into pDest-737 to
generate an expression construct with CMV promoter and N-
terminal 3xFLAG tag. Full-length BRMS1 was epitope tagged at
the N-terminus by PCR with the HA or myc tag sequence
incorporated into the forward primer and cloned into pCMV or
pcDNA3-hygro (Invitrogen), respectively. Correct sequences of all
vectors were confirmed prior to use.
Cell culture and stable cell lines
Met-1 cells [10] were a gift from Dr. Robert Cardiff (University
of California, Davis, CA). 6DT1 cells [11] were a gift from Dr.
Lalage Wakefield (NCI, NIH, Bethesda, MD). HEK293 cells were
purchased from ATCC (Manassas, VA). Cell lines were main-
tained in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, penicillin and streptomycin. Cells were confirmed to
be free of mycoplasma contamination using the MycoAlert
detection kit (Lonza).
Met-1 cells seeded onto 10 cm tissue culture plates were co-
transfected with 6 mg of the appropriate V5-tagged Arid4b
construct described above, or pcDNA3.1/V5-His-TOPO/lacZ
(Invitrogen) as a control vector, plus 600 ng of pSuper.Retro.Puro
(Oligoengine) as a selectable marker, using FuGENE 6 transfec-
tion reagent. Cells were selected using 1 mg/ml G418 plus 4 mg/
ml puromycin and clones derived by limiting dilution. Stable
upregulation of Arid4b was verified by performing QRT-PCR
using forward primer 59- GGTGAGTGGGAGCTGGTCTA-39
and reverse primer 59- ATAAAGGGCCCACTGAAGGT-39, and
western blotting for endogenous and ectopically expressed
ARID4B as described below. 6DT1 cells were transduced with
one of five different lentiviral shRNAs targeting Arid4b
(RMM4534-NM_194262, Open Biosystems) or a scrambled
control shRNA in the same pLKO.1 vector. Stable cells were
selected using 10 mg/ml puromycin and pooled clones were
analyzed for Arid4b knockdown by western blot.
Animal studies
Met-1 or 6DT1 stable lines were orthotopically implanted into
the fourth mammary fat pad of six week old female NU/J or
FVB/NJ mice using 10
5 cells suspended in 100 ml of PBS per
animal. Primary tumors and lungs were harvested 28 days later.
All experiments were performed according to the National Cancer
Institute Animal Care and Use Committee guidelines.
Migration and invasion assays
Met-1 cells stably expressing Arid4b or lacZ were seeded at
75,000 cells per well into invasion chambers coated with Matrigel
basement membrane matrix (534480, BD Biosciences) or control
chambers lacking Matrigel (354578, BD Biosciences). After
24 hours, cells were fixed in 100% methanol, stained with crystal
violet, and mounted onto glass slides using mineral oil. Cells were
visualized at 4006magnification and five fields were counted for
each of three experiments.
Co-immunoprecipitations
HEK293 cells were transfected with the V5- or FLAG-tagged
AKR or DBA allele of Arid4b, with or without HA-BRMS1 or
myc-BRMS1 where appropriate, using FuGENE 6 transfection
reagent. After 30 hours, cells were harvested in mild IP lysis buffer
(25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-
40, 5% glycerol) supplemented with protease inhibitors
(11836170001, Roche) and phosphatase inhibitors (P-5726,
Sigma). Protein samples were quantitated using Bradford assays.
Gammabind G Sepharose beads (17088501, GE Healthcare) were
washed twice in NET buffer (50 mM Tris pH 8.0, 150 mM NaCl,
5 mM EDTA, 1% NP-40, 0.5% BSA, 0.04% sodium azide)
supplemented with protease and phosphatase inhibitors, and
resuspended to form a 50% bead slurry. Lysates were precleared
by adding 40 ml of bead slurry and rotating for 30 minutes at 4uC.
Samples were centrifuged at 10,000 rpm for 1 minute at 4uC and
pre-cleared supernatant transferred to a fresh tube. Anti-V5, anti-
FLAG, or anti-myc tag antibodies was added to a final
concentration of 1.0 mg/ml and samples rotated for 1 hour at
4uC, then 50 ml of bead slurry was added and co-IPs performed
overnight at 4uC. Beads were then washed four times with NET
buffer and resuspended in SDS-PAGE sample buffer.
Western blots and densitometry
NuPAGE precast gels and buffers (Invitrogen) were used
according to manufacturers recommendations and gels were
transferred onto Immobilon-P (Millipore). Membranes were
blocked in TBS with 0.5% Tween-20 (TBST) plus 5% nonfat
dry milk for 1 hour at room temperature then incubated with the
primary antibody diluted in blocking buffer overnight at 4uC. The
following primary antibodies and concentrations were used: anti-
Arid4b (1:3,000; A302-233A, Bethyl Laboratories), anti-V5
(1:5,000; 37–7500, Invitrogen), anti-mSIN3A (1:1,000; sc-994,
Santa Cruz), anti-mSDS3 (1:2,000; A300-235A, Bethyl Labs),
anti-b-actin (1:10,000; ab6276, Abcam), anti-FLAG (1:3,000; F-
3165, Sigma), anti-HA (1:5,000; 11867423001, Roche), anti-myc
tag (1:2,000; 2276, Cell Signaling). After three washes in TBST,
membranes were incubated with one of the following horseradish
peroxidase conjugated secondary antibodies diluted in TBST plus
0.5% milk for 1 hour at room temperature: anti-mouse (1:5,000;
NA931V, GE Healthcare), anti-rabbit (1:10,000; sc-2004, Santa
Cruz), anti-goat (1:10,000; sc-2304, Santa Cruz). Membranes were
washed an additional three times in TBST and proteins detected
using the Amersham ECL Plus system (RPN2132, GE Healthcare)
and Amersham Hyperfilm ECL (28906837, GE Healthcare)
according to manufacturer’s recommendations. Densitometry
data were collected and analyzed using a ChemiDoc-It Imaging
System and VisionWorksLS software (UVP).
Expression profiling and network analysis
Total RNA was isolated from pooled clones of 6DT1 Arid4b
knockdown cell lines using RNeasy kits (Qiagen) and then arrayed
on Affymetrix GeneChip Mouse Gene 1.0 ST arrays by the
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ogy. Expression data were normalized using Partek Genomics
Suite to identify genes whose expression was significantly different
(p,.05) between the Arid4b normal cohort (untreated, scrambled
control, and H5 lines) and the Arid4b knockdown cohort (lines H3
and H4). The gene list and expression values were then analyzed
using Ingenuity Pathways Analysis (Ingenuity Systems, www.
ingenuity.com) to identify differentially regulated signaling path-
ways and biological functions. Expression of the Tpx2 transcrip-
tional network was visualized and figure generated using
Cytoscape software [39]. Microarray data are available through
the Gene Expression Omnibus under accession number
GSE35731.
Supporting Information
Figure S1 Interval mapping for metastatic progression in the
AKXD recombinant inbred panel. A potential QTL peak was
detected on proximal chromosome 13. Likelihood ratio score
(LRS) for correlation with metastasis is shown in blue with the
AKR genotype in red and the DBA genotype in green.
(TIF)
Figure S2 Quantitation of Arid4b expression in stable cell lines.
QRT-PCR data (A) was internally normalized to Ppib and fold
change expressed relative to Met-1 cells stably expressing lacZ.
Western blots confirm upregulation of the AKR and DBA alleles at
theproteinlevelrelativetoendogenousexpressioninlacZ controls(B).
(TIF)
Figure S3 High resolution map of Tpx2 network gene expression
in Arid4b knockdown cell lines. Red indicates statistically
significant (p,.05, ANOVA) downregulation; green indicates
upregulation.
(TIF)
Figure S4 ARID4B mRNA expression in ductal breast carcino-
ma versus normal breast tissue. Dots represent minimum and
maximum values, whisker bars represent 10
th and 90
th percentiles,
boxes represent 25
th to 75
th percentiles, and center bars represent
median values. Fold change was 2.299 and statistical significance
was determined by two-tailed t-test. Figure adapted from
Oncomine representation of ARID4B expression in the Richardson
breast cancer data set [15].
(TIF)
Table S1 Arid4b exon amplification and sequencing primers.
(DOC)
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